טוען...
Plasmablastic lymphoma after standard-dose temozolomide for newly diagnosed glioblastoma
Secondary malignancies due to alkylating agents or topoisomerase II inhibitors are a concern in patients treated for primary brain tumors of the nervous system. Myelosuppression is the dose-limiting toxic effect of the alkylating agent temozolomide; reversible hematologic toxicity consisting mainly...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Lippincott Williams & Wilkins
2013
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3770207/ https://ncbi.nlm.nih.gov/pubmed/23685934 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e318297eea6 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|